Specialty Pharma Journal Specialty, Precision & Technology
REDWOOD CITY, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that Celgene has notified OncoMed that due to strategic product portfolio considerations Celgene has decided not to exercise its option to license …
Tag Archives: OncoMed
September, 2018
April, 2017
-
17 April
OncoMed’s Tarextumab Misses Primary Endpoint in Mid-Stage Lung Cancer Trial
REDWOOD CITY, Calif., April 17, 2017 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today reported top-line results from the company’s randomized 145-patient Phase 2 PINNACLE clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) in combination with …
-
10 April
OncoMed’s Demcizumab Misses Primary Endpoint in Mid-Stage Pancreatic Cancer Trial
REDWOOD CITY, Calif., April 10, 2017 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today reported top-line results from the company’s Phase 2 YOSEMITE clinical trial of demcizumab (anti-DLL4, OMP-21M18) in combination with Abraxane® (paclitaxel …
April, 2015
-
2 April
OncoMed to Investigate the Combination of its Experimental Cancer Drug with Lilly’s Alimta in Lung Cancer
OncoMed Pharmaceuticals, Inc. has teamed up with Eli Lilly and Company to test a combination of the companies’ drugs for treatment of lung cancer. The companies announced that they have entered into an agreement, under which OncoMed’s anti-DLL4 antibody, demcizumab, is being tested in combination with Lilly’s lung cancer drug, …